As a Free StocksGuide user, you can view scores for all 7,011 stocks worldwide.
26 Analysts have issued a ACADIA Pharmaceuticals Inc. forecast:
26 Analysts have issued a ACADIA Pharmaceuticals Inc. forecast:
Jun '25 |
+/-
%
|
||
Revenue | 1,019 1,019 |
14%
14%
|
|
Gross Profit | 937 937 |
15%
15%
|
|
EBITDA | 250 250 |
645%
645%
|
EBIT (Operating Income) EBIT | 237 237 |
969%
969%
|
Net Profit | 222 222 |
626%
626%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
ACADIA Pharmaceuticals, Inc. operates as a biopharmaceutical company focused on the development and commercialization of medicines to address unmet medical needs in central nervous system, or CNS, disorders. The firms product include Nuplazid, which is used for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. The company was founded by Mark R. Brann on July 16, 1993 and is headquartered in San Diego, CA.
Head office | United States |
CEO | Catherine Adams |
Employees | 654 |
Founded | 1993 |
Website | acadia.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.